Comments on new JAMA study, looking for changes in risks in longer-term follow-up of estrogen therapy

Current article ratings:
Patients / public:healthcare Prof:1 (1 votes)
Rowan t. Chlebowski, co-author of the study and a medical oncologist at the Los Angeles Biomedical Research Institute, published several important research articles about the relationship between estrogen and progestin therapy and breast cancer.

The study found in postmenopausal women with prior hysterectomy, the estrogen therapy for about six years and then stopped, longer-term follow-up specifying, that while the intervention period had seen the increased risk of stroke dissipated, and the reduced risk of a hip fracture was not maintained, while maintaining the reduced risk of breast cancer. You can read the full article here.

The following comments are Dr. Chlebowski:

"Be found the reduced breast cancer incidence of study among the women, the estrogen alone on the trend, which we previously reported." More important is, are these results of the impact of taking combined estrogen plus progestin therapy vary. "Our studies found the combination of estrogen and progestin is breast cancer incidence and breast cancer mortality."

Source code
LA BioMed